Financial Performance - The company's operating revenue for Q1 2024 was RMB 1,373,251,921.93, representing a 5.55% increase compared to RMB 1,301,021,684.04 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2024 was RMB 155,040,262.39, a significant increase of 133.00% from RMB 66,540,023.25 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 157,052,354.18, reflecting a 253.00% increase from RMB 44,491,211.83 year-on-year[3]. - Basic and diluted earnings per share for Q1 2024 were both RMB 0.1057, up 133.33% from RMB 0.0453 in the previous year[3]. - Operating profit for the reporting period reached RMB 196.85 million, a 167.28% increase compared to the same period last year, primarily due to increased gross profit and reduced expenses[9]. - The total profit for the current period is RMB 181,205,852.66, a significant increase of 133.3% compared to RMB 77,557,847.95 in the previous period[24]. - Net profit attributable to the parent company is RMB 155,040,262.39, up from RMB 66,540,023.25, representing a growth of 132.7%[24]. - The operating profit for the current period is RMB 196,847,737.66, compared to RMB 73,649,081.61 in the previous period, indicating an increase of 167.1%[24]. - The total comprehensive income for the current period is RMB 150,135,056.48, which is an increase of 142.3% from RMB 61,856,551.06 in the previous period[26]. Cash Flow - The net cash flow from operating activities reached RMB 880,453,882.15, a remarkable turnaround from a negative cash flow of RMB -213,979,198.80 in the same period last year, marking a 511.47% improvement[3]. - Cash inflow from operating activities is RMB 1,664,646,503.27, down from RMB 1,936,382,607.31, a decrease of 14%[27]. - Cash outflow from operating activities totals RMB 784,192,621.12, a decrease from RMB 2,150,361,806.11, indicating a reduction of 63.5%[28]. - Net cash flow from operating activities is RMB 880,453,882.15, a significant recovery from a negative cash flow of RMB -213,979,198.80 in the previous period[28]. - Cash inflow from investment activities is RMB 441,112,963.21, down from RMB 1,206,613,179.47, a decrease of 63.4%[28]. - Net cash flow from investment activities is RMB 130,688,287.99, a decrease of 83.6% compared to RMB 795,650,734.04 in the previous period[28]. - Cash inflow from financing activities totaled approximately ¥835.83 million, down from ¥1,604.26 million in the previous period, representing a decrease of about 47.9%[29]. - Cash outflow from financing activities amounted to approximately ¥1,506.67 million, compared to ¥1,723.83 million last period, indicating a decrease of about 12.6%[29]. - Net cash flow from financing activities was negative at approximately -¥670.83 million, worsening from -¥119.57 million in the previous period[29]. - The net increase in cash and cash equivalents for the period was approximately ¥342.74 million, down from ¥433.44 million in the previous period[29]. - The ending balance of cash and cash equivalents reached approximately ¥2,108.38 million, an increase from ¥1,753.15 million in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,874,970,670.54, a decrease of 1.71% from RMB 19,203,415,131.24 at the end of the previous year[3]. - Total liabilities decreased to RMB 6,736,457,897.24 from RMB 7,215,037,414.42, reflecting a reduction of about 6.6%[21]. - The company's total equity increased to RMB 12,138,512,773.30 from RMB 11,988,377,716.82, reflecting a growth of approximately 1.3%[22]. - Cash and cash equivalents at the end of the period were RMB 2,225,125,933.99, compared to RMB 1,851,642,224.58 at the beginning of the period, showing an increase of about 20.2%[18]. - Inventory decreased to RMB 6,341,627,515.17 from RMB 6,654,110,787.81, indicating a decline of approximately 4.7%[18]. - Long-term equity investments decreased to RMB 943,735,674.53 from RMB 1,004,045,899.43, a decrease of about 6.0%[19]. - Total operating costs decreased to RMB 1,184,463,117.86 from RMB 1,239,337,824.93, indicating a reduction of about 4.4%[23]. Research and Development - Research and development expenses for Q1 2024 were RMB 35,294,968.25, an increase of 33.11% compared to RMB 26,514,765.57 in the same period last year[8]. - Research and development expenses increased to RMB 35,294,968.25, up from RMB 26,514,765.57, representing a growth of approximately 33.2%[23]. Market Strategy - The company plans to accelerate its sales strategy in New Zealand and Thailand following the approval of its heparin sodium injection in these markets[11]. - The company is focusing on expanding its market share in the heparin sodium formulation business, ranking second in sales in Europe during the reporting period[12]. - The CDMO business has shown significant revenue growth compared to the previous year, driven by the integration of resources and expansion of customer base[13]. - The company aims to enhance its development momentum and fully leverage its competitive advantages to achieve breakthrough growth in 2024[14]. - The focus will be on expanding sales in key overseas markets, particularly in Europe and the United States, while also targeting new non-European and non-American markets[14]. - In the heparin industry chain, the company will continue to prioritize centralized procurement in the Chinese market to drive sales growth[14]. - The company plans to implement a dual-driven platform strategy in its CDMO segment to maximize project value for clients and improve the success rate of ongoing projects[14]. Shareholder Information - The company reported a total of 28,328 common shareholders at the end of the reporting period, with the top two shareholders holding 60.12% of the shares[15]. - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of the shares, while Xiamen Jintian Soil Investment Partnership holds 27.81%[15]. Financial Incidents - The company experienced a telecom fraud incident involving approximately €11.7 million, with an impact of RMB 15.56 million on pre-tax profit and net profit for 2024[17]. - The actual controller of the company provided an advance payment of RMB 89.81 million to safeguard the interests of the company and its investors[17]. Financial Management - The company is actively managing its financial structure and cost control to balance financial risks and reduce capital costs[11]. - The company will continue to adopt prudent financial and liquidity management to enhance management efficiency and risk control[14]. - The company is committed to maximizing asset value and improving profitability through resource integration and strategic investments[14].
海普瑞(09989) - 2024 Q1 - 季度业绩